Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
- De Bruyn, Pauline
- Van Gestel, Dirk
- Ost, Piet
- Kruse, Vibeke
- Brochez, Lieve
- Van Vlierberghe, Hans
- Devresse, Arnaud
- Del Marmol, Véronique
- Le Moine, Alain
- Aspeslagh, Sandrine
Publication date
February 2019
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
Checkpoint inhibitors (CPIs) provide impressive response rates among immunocompetent patients with various solid tumors. So far, organ transplant recipients have been excluded from clinical studies due to the putative risk of allograft rejection however 48 cases of liver and renal transplant patients treated with CPI were already described in literature.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG